Steven Kelly's most recent trade in Carisma Therapeutics Inc was a trade of 500,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Carisma Therapeutics Inc | Steven Kelly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Artelo Biosciences Inc | Kelly Steven | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2024 | 1,750 | 1,750 | - | - | Stock Option (right to buy) | |
| Carisma Therapeutics Inc | Steven Kelly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Artelo Biosciences Inc | Steven Kelly | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 Feb 2024 | 9,634 | 0 | - | - | Stock Option (right to buy) | |
| Artelo Biosciences Inc | Steven Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 9,634 | 9,634 | - | - | Stock Option (right to buy) | |
| Artelo Biosciences Inc | Steven Kelly | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 Feb 2024 | 1,484 | 0 | - | - | Stock Option (right to buy) | |
| Artelo Biosciences Inc | Steven Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 1,484 | 1,484 | - | - | Stock Option (right to buy) | |
| Artelo Biosciences Inc | Steven Kelly | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 Feb 2024 | 1,083 | 0 | - | - | Stock Option (right to buy) | |
| Artelo Biosciences Inc | Steven Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 1,083 | 1,083 | - | - | Stock Option (right to buy) | |
| Artelo Biosciences Inc | Steven Kelly | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 Feb 2024 | 667 | 0 | - | - | Stock Option (right to buy) | |
| Artelo Biosciences Inc | Steven Kelly | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 Feb 2024 | 667 | 0 | - | - | Stock Option (right to buy) | |
| Artelo Biosciences Inc | Steven Kelly | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 Feb 2024 | 667 | 0 | - | - | Stock Option (right to buy) | |
| Artelo Biosciences Inc | Steven Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 667 | 667 | - | - | Stock Option (right to buy) | |
| Artelo Biosciences Inc | Steven Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 667 | 667 | - | - | Stock Option (right to buy) | |
| Artelo Biosciences Inc | Steven Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 667 | 667 | - | - | Stock Option (right to buy) | |
| Carisma Therapeutics Inc | Steven Kelly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 438,000 | 438,000 | - | - | Stock Option (Right to Buy) | |
| Artelo Biosciences Inc | Steven Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Aug 2023 | 1,083 | 1,083 | - | - | Stock Option (right to buy) | |
| Artelo Biosciences Inc | Steven Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 667 | 667 | - | - | Stock Option (right to buy) | |
| Carisma Therapeutics Inc | Steven Kelly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 600,000 | 600,000 | - | - | Stock Option (Right to Buy) | |
| Globe Life | Steven Kelly Greer | Exec. Officer Principal Sub | Exercise or conversion of derivative security received from the company (such as an option) at price $ 50.64 per share. | 01 Nov 2022 | 18,000 | 34,143 (0%) | 0% | 50.6 | 911,520 | Common Stock |
| Globe Life | Steven Kelly Greer | Exec. Officer Principal Sub | Sale of securities on an exchange or to another person at price $ 113.47 per share. | 01 Nov 2022 | 18,000 | 16,239 (0%) | 0% | 113.5 | 2,042,374 | Common Stock |
| Globe Life | Steven Kelly Greer | Exec. Officer Principal Sub | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2022 | 18,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Artelo Biosciences Inc | Steven Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Globe Life | Steven Kelly Greer | Exec. Officer Principal Sub | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 40,000 | 40,000 | - | - | Employee Stock Option (Right to Buy) | |
| Globe Life | Steven Kelly Greer | Exec. Officer Principal Sub | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 3,584 | 17,554 (0%) | 0% | 0 | Common Stock | |
| Globe Life | Steven Kelly Greer | Exec. Officer Principal Sub | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.23 per share. | 23 Feb 2022 | 1,411 | 16,143 (0%) | 0% | 103.2 | 145,658 | Common Stock |
| Globe Life | Steven Kelly Greer | Exec. Officer Principal Sub | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2022 | 17,000 | 18,000 | - | - | Employee Stock Option (Right to Buy) | |
| Globe Life | Steven Kelly Greer | Exec. Officer Principal Sub | Sale of securities on an exchange or to another person at price $ 106.53 per share. | 11 Feb 2022 | 17,000 | 13,970 (0%) | 0% | 106.5 | 1,810,928 | Common Stock |
| Globe Life | Steven Kelly Greer | Exec. Officer Principal Sub | Exercise or conversion of derivative security received from the company (such as an option) at price $ 50.64 per share. | 11 Feb 2022 | 17,000 | 30,970 (0%) | 0% | 50.6 | 860,880 | Common Stock |
| Globe Life | Steven Kelly Greer | Exec. Officer of Principal Sub | Sale of securities on an exchange or to another person at price $ 104.78 per share. | 04 Feb 2022 | 4,311 | 15,885 (0%) | 0% | 104.8 | 451,702 | Common Stock |
| Globe Life | Steven Kelly Greer | Exec. Officer of Principal Sub | Sale of securities on an exchange or to another person at price $ 104.65 per share. | 04 Feb 2022 | 1,915 | 13,970 (0%) | 0% | 104.7 | 200,410 | Common Stock |
| Artelo Biosciences Inc | Steven Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Globe Life | Steven Kelly Greer | Exec Officer Principal Sub | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 40,000 | 40,000 | - | - | Employee Stock Option (right to buy) | |
| Globe Life | Steven Kelly Greer | Exec Officer Principal Sub | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 11,408 | 23,402 (0%) | 0% | 0 | Common Stock | |
| Globe Life | Steven Kelly Greer | Exec Officer Principal Sub | Payment of exercise price or tax liability using portion of securities received from the company at price $ 98.32 per share. | 24 Feb 2021 | 3,369 | 20,033 (0%) | 0% | 98.3 | 331,240 | Common Stock |
| Artelo Biosciences Inc | Steven Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 144,500 | 144,500 | - | - | Stock Option (right to buy) |